IP Library Assignment 043045/0959
Patent Assignment
Reel/Frame 043045/0959

Security Interest

Recorded: 2017-07-19 Pages: 9
Assignor
Assignee
THE BANK OF NEW YORK MELLON
101 BARCLAY STREET, FLOOR 7E, NEW YORK, NEW YORK, 10286
Covered Properties (30)
Methods, Compositions and Articles for Reducing or Preventing the Effects of Inflammation
Patent: 6,274,614 →
Application: 08/942,883 →
Ethylene Glycol Esters as Photoactive Agents
Patent: 5,929,105 →
Application: 09/088,524 →
Model and Method for Angiogenesis Inhibition
Patent: 6,117,862 →
Application: 09/169,735 →
Ethylene Glycol Esters as Photoactive Agents
Patent: 6,153,639 →
Application: 09/313,106 →
Ethylene Glycol Esters as Photoactive Agents
Patent: 6,756,396 →
Application: 09/588,206 →
Drug Delivery System for Hydrophobic Drugs
Patent: 6,984,395 →
Application: 09/833,406 →
Publication: US 2002/0156062
Methods, Compositions and Articles for Reducing or Preventing the Effects of Inflammation
Patent: 6,677,366 →
Application: 09/929,558 →
Publication: US 2002/0103180
Reduced Fluence Rate Pdt
Patent: 6,800,086 →
Application: 10/072,009 →
Publication: US 2002/0173832
Method to Prevent Vision Loss
Patent: 7,060,695 →
Application: 10/072,215 →
Publication: US 2002/0183302
Photodynamic Therapy of Occult Age-Related Macular Degeneration
Patent: 8,034,803 →
Application: 10/072,272 →
Publication: US 2003/0087889
Method for Reducing or Preventing Pdt Related Inflammation
Patent: 8,106,038 →
Application: 10/081,010 →
Publication: US 2003/0083649
Treatment of Macular Edema
Patent: 6,599,891 →
Application: 10/199,662 →
Publication: US 2003/0099596
Compositions and Methods for Delivery of Photosensitive Drugs
Patent: 7,455,858 →
Application: 10/440,505 →
Publication: US 2004/0047913
Treatment of Macular Edema
Patent: 7,015,240 →
Application: 10/622,310 →
Publication: US 2004/0019032
Reduced Fluence Rate Pdt
Patent: 7,753,943 →
Application: 10/641,885 →
Publication: US 2004/0122491
Ethylene Glycol Esters as Photoactive Agents
Patent: 7,122,569 →
Application: 10/825,270 →
Publication: US 2005/0032769
Immuno-Adjuvant Pdt Treatment of Metastatic Tumors
Patent: 7,850,981 →
Application: 10/985,582 →
Publication: US 2005/0187207
Teeth Whitening Composition and Methods
Patent: 8,075,875 →
Application: 11/598,206 →
Publication: US 2007/0128132
Method for Treating Neovascularization
Patent: 8,158,669 →
Application: 11/975,325 →
Publication: US 2008/0096865
Drug Delivery System for Hydrophobic Drugs
Patent: 8,852,629 →
Application: 12/487,964 →
Publication: US 2010/0247447
Photopolymerization Material for Gums Isolation
Patent: 8,334,328 →
Application: 12/525,890 →
Publication: US 2010/0152296
Photodynamic Therapy for Conditions of the Eye
Patent: 9,226,917 →
Application: 13/140,411 →
Publication: US 2012/0041356
Photodynamic Therapy Laser
Patent: 9,211,214 →
Application: 13/426,470 →
Publication: US 2013/0253411
Method for Treating Neovascularization
Patent: 8,862,224 →
Application: 13/448,242 →
Publication: US 2012/0203162
Device and Method for Teeth Brightening
Application: 13/863,529 →
Publication: US 2013/0337403
Controlled Release Microparticles
Application: 14/489,863 →
Publication: US 2015/0037429
Multidose Package, Course and Method of Treatment for Delivering Predetermined Multiple Doses of a Pharmaceutical
Application: 14/629,176 →
Publication: US 2015/0174120
Photodynamic Therapy Laser
Patent: 9,949,877 →
Application: 14/872,248 →
Publication: US 2016/0074222
Formulations of Calcium and Phosphate for Oral Inflammation
Application: 14/945,865 →
Publication: US 2016/0175356
Compositions and Methods for Teeth Whitening
Patent: 9,655,829 →
Application: 15/006,943 →
Publication: US 2016/0136075
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Patent Assignment Agreement Dec 9, 2013
From: QLT INC.; QLT OPHTHALMICS, INC.
To: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Reel/Frame 031784/0833 →
Assignment of Assignor's Interest May 20, 2016
From: KLOX TECHNOLOGIES INC.
To: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Reel/Frame 038654/0239 →
Security Interest Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
Security Interest Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
Security Interest Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
Intellectual Property Security Agreement Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
Security Interest Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
Security Agreement (First Lien) Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
Security Agreement (Second Lien) Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
Security Agreement (Second Lien) Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
Security Agreement (First Lien) Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
Assignment of Assignor's Interest Jan 13, 2023
From: BAUSCH HEALTH COMPANIES INC.
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 062375/0428 →
Change of Name Jan 13, 2023
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: BAUSCH HEALTH COMPANIES INC.
Reel/Frame 062389/0306 →
Security Interest Feb 13, 2023
From: BAUSCH HEALTH COMPANIES INC.; VALEANT CANADA LP; VALEANT CANADA GP LIMITED; V-BAC HOLDING CORP.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 062670/0260 →
Security Interest Mar 15, 2023
From: BAUSCH HEALTH COMPANIES INC.; VALEANT CANADA LP; VALEANT CANADA GP LIMITED; V-BAC HOLDING CORP.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 062983/0494 →
Intellectual Property Security Agreement Nov 29, 2023
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 065709/0253 →
Security Interest Feb 12, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 066552/0041 →
Release of Security Interest in Specified Patents (Reel/Frame 045444/0299) Apr 17, 2024
From: BARCLAYS BANK PLC
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0587 →
Release of Security Interest in Specified Patents (Reel/Frame 039380/0385) Apr 17, 2024
From: BARCLAYS BANK PLC
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0578 →
Omnibus Patent Security Release Agreement (Reel/Frame 057821/0800) Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0651 →
Omnibus Patent Security Release Agreement (Reel/Frame 049672/0652) Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0618 →
Omnibus Patent Security Release Agreement (Reel/Frame 045444/0634) Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0596 →
Release of Security Interest Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.
Reel/Frame 070778/0199 →
Release of Security Interest Apr 14, 2025
From: BARCLAYS BANK PLC
To: BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH COMPANIES INC.
Reel/Frame 070830/0577 →
Change of Name May 1, 2025
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: BAUSCH HEALTH COMPANIES INC.
Reel/Frame 070996/0143 →